Cancer Horoscope Tomorrow for April 16, 2025, to know your astrological predictions. Take a pause before throwing all your ...

The most common types of cancers estimated to be a result of CT scans were lung cancer and colon cancer—two cancers that are ...

Iovance's Amtagvi is the first TIL therapy approved by the U.S. Food and Drug Administration (FDA). Its first approved ...

Researchers have found that tapping into the body's own immune system and activating a type of immune cell known as B cells, could be the key to boosting the effectiveness of tumor-infiltrating ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic ...

Researchers have explored the evolution of the genetic change that causes chronic myeloid leukaemia and show its ability to drive the disease.

Bayer's Vitrakvi receives full FDA approval based on solid tumor data showing sustained efficacy in NTRK fusion-positive patients.

Four leading companies CTMC, Iovance Therapeutics, KSQ, and TILT Biotherapeutics prognosticate coming successes of new technology approaches to better tumor-infiltrating lymphocyte activities.

Revive Therapeutics (RVVTF) announced that it has been contacted by a prominent clinical researcher from a U.S. University Cancer Institute.

Researchers have unlocked a powerful new way to fight solid tumors using smart immune cells that stay active longer and hit ...

Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric ...